Literature DB >> 14984265

Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol.

Ellen Q Wang1, Joseph P Balthasar, Ho-Leung Fung.   

Abstract

PURPOSE: We examined the effects of dose and dosing protocol on the pharmacodynamics of in vivo nitroglycerin (NTG) tolerance in conscious rats. Mechanism-based pharmcokinetic/pharmacodynamic (PK/PD) models were tested for their ability to describe the observed data.
METHODS: Rats were infused with 1, 3, or 10 microg/min of NTG or vehicle for 10 h. Peak mean arterial pressure (MAP) response to an hourly 30 microg i.v. NTG challenge dose (CD) was measured before, during, and at 12 and 24 h after infusion. In separate experiments, the MAP effects of repeated bolus doses of NTG were compared to those after a continuous infusion, both at a total dose of 510 microg NTG.
RESULTS: NTG tolerance was indicated by a decrease in peak MAP response to the CD, relative to the preinfusion peak MAP response. Tolerance toward the MAP effects of bolus CD was observed within 1 h of 10 microg/min of NTG infusion (26.8 +/- 2.8% vs. 10.6 +/- 0.4% for 0 and 1 h, respectively, p < 0.001), and the rate and extent of tolerance development increased with the infusion dose. No apparent MAP tolerance was observed when NTG was given as multiple bolus doses whereas significant MAP tolerance was observed when this dose was infused continuously. PK/PD modeling indicated that a cofactor/enzyme depletion mechanism could adequately describe the composite data.
CONCLUSIONS: Our data showed that in vivo nitrate tolerance was dose- and dosing protocol-dependent. The pharmacodynamics of tolerance development are consistent with depletion of either critical enzymes or cofactors that are necessary to induce vasodilation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984265     DOI: 10.1023/b:pham.0000012158.80991.7e

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

1.  Dissociation of nitrovasodilator-induced relaxation from cyclic GMP levels during in vitro nitrate tolerance.

Authors:  E A Kowaluk; H L Fung
Journal:  Eur J Pharmacol       Date:  1990-01-25       Impact factor: 4.432

2.  Prevention of tolerance to nitroglycerin patches by overnight removal.

Authors:  J C Cowan; J P Bourke; D S Reid; D G Julian
Journal:  Am J Cardiol       Date:  1987-08-01       Impact factor: 2.778

3.  Mechanism of tolerance development to organic nitrates.

Authors:  P Needleman; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

4.  Effects of guanylyl cyclase and protein kinase G inhibitors on vasodilatation in non-tolerant and tolerant bovine coronary arteries.

Authors:  I S De la Lande; I Stafford; J D Horowitz
Journal:  Eur J Pharmacol       Date:  1999-04-01       Impact factor: 4.432

5.  Possible involvement of nitroglycerin converting step in nitroglycerin tolerance.

Authors:  K Hasegawa; T Taniguchi; K Takakura; Y Goto; I Muramatsu
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

6.  Blood vessel uptake and metabolism of organic nitrates in the rat.

Authors:  H L Fung; S C Sutton; A Kamiya
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

Review 7.  Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.

Authors:  Robert Morris; Adnan Munkarah
Journal:  Oncologist       Date:  2002

8.  Pharmacokinetics of nitroglycerin in rats.

Authors:  P S Yap; H L Fung
Journal:  J Pharm Sci       Date:  1978-04       Impact factor: 3.534

9.  Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.

Authors:  T Münzel; H Sayegh; B A Freeman; M M Tarpey; D G Harrison
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production. Probes with inhibitors and tolerance development.

Authors:  S J Chung; H L Fung
Journal:  Biochem Pharmacol       Date:  1993-01-07       Impact factor: 5.858

View more
  2 in total

1.  Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease.

Authors:  Rana T Alhashimi; Mohini S Ghatge; Akua K Donkor; Tanvi M Deshpande; Nancy Anabaraonye; Dina Alramadhani; Richmond Danso-Danquah; Boshi Huang; Yan Zhang; Faik N Musayev; Osheiza Abdulmalik; Martin K Safo
Journal:  Biomolecules       Date:  2022-05-12

2.  Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin-NO Biochemistry.

Authors:  Guoyan G Xu; Tanvi M Deshpande; Mohini S Ghatge; Akul Y Mehta; Abdel Sattar M Omar; Mostafa H Ahmed; Jurgen Venitz; Osheiza Abdulmalik; Yan Zhang; Martin K Safo
Journal:  Biochemistry       Date:  2015-12-03       Impact factor: 3.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.